Table 5 Comparison between factors and occurrence of drug use problems, drug interactions, and other problems

Elderly

Yes

17 (34.0)

68 (45.3)

0.215^a

37 (58.7)

78 (56.9)

0.933^a

57 (58.8)

58 (56.3)

0.836^a

No

33 (66.0)

82 (54.7)

26 (41.3)

59 (43.1)

40 (41.2)

45 (43.7)

Polypharmacy

Yes

34 (68.0)

119 (79.3)

0.149^a

58 (92.1)

95 (69.3)

0.001^a*

74 (76.3)

79 (76.7)

> 0.999^a

No

16 (32.0)

31 (20.7)

5 (7.9)

42 (30.7)

23 (23.7)

24 (23.3)

Duration of hospital stay

≤ 1 week

37 (74.0)

106 (70.7)

0.786^a

44 (69.8)

99 (72.3)

0.854^a

65 (67.0)

78 (75.7)

0.227^a

> 1 week

13 (26.0)

44 (29.3)

19 (30.2)

38 (27.7)

32 (33.0)

25 (24.3)

Microvascular complications

Yes

31 (62.0)

93 (62.0)

> 0.999^a

41 (65.1)

83 (60.6)

0.652^a

65 (67.0)

59 (57.3)

0.204^a

No

19 (38.0)

57 (38.0)

22 (34.9)

54 (39.4)

32 (33.0)

44 (42.7)

Cardiovascular disease

Yes

27 (54.0)

94 (62.7)

0.358^a

53 (84.1)

68 (49.6)

< 0.001^a*

63 (64.9)

58 (56.3)

0.270^a

No

23 (46.0)

56 (37.3)

10 (15.9)

69 (50.4)

34 (35.1)

45 (43.7)

Renal impairment

Yes

22 (44.0)

78 (52.0)

0.414^a

33 (52.4)

67 (48.9)

0.761^a

49 (50.5)

51 (49.5)

> 0.999^a

No

28 (56.0)

72 (48.0)

30 (47.6)

70 (51.1)

48 (49.5)

52 (50.5)

Liver impairement

Yes

4 (8.0)

7 (4.7)

0.472^b

0 (0)

11 (8.0)

0.018^b*

5 (5.2)

5 (5.8)

> 0.999^a

No

46 (92.0)

143 (95.3)

63 (100)

126 (92.0)

92 (94.8)

97 (94.2)

Hyperlipidemia

Yes

17 (34.0)

68 (45.3)

37 (58.7)

78 (56.9)

57 (58.8)

58 (56.3)

0.836^a

No

33 (66.0)

82 (54.7)

0.215^a

26 (41.3)

59 (43.1)

0.933^a

40 (41.2)

45 (43.7)